Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

D3S 001

Next Previous
X
Search
Drug Profile

D3S 001

Alternative Names: D3S-001

Latest Information Update: 02 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator D3 Bio
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 25 Nov 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumour released by D3 Bio
  • 23 Oct 2024 Updated pharmacodynamics data from preclinical trials in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
  • 08 Apr 2024 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Combination therapy) (unspecified route), prior to April 2024 (D3 Bio pipeline, April 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top